CybeRelease: (OTC: MNCL) in Negotiations for Marketing and Distribution Rights of Its Products in Spain and Portugal

(CybeRelease, March 19, 2007) – Lake Harmony, Pa. - Martin Nutraceuticals Inc. (OTC PK: MNCL) announced that they have begun negotiations with X Consul Group to distribute Martin’s flagship product Arthrizyme, in Portugal and Spain.

Several opportunities exist for a successful market entry, by Martin Nutraceuticals, in Spain and Portugal with X Consul Group, the third largest distributor of dietary supplements in Spain and Portugal. With a vastly aging population stimulating the growth of dietary supplements, X Consul Group is looking to expand its product range to include products that will target specific vital segments, including arthritis and general joint pain.

With a significant percentage of its general population over the age of 60, Spain and Portugal are expected to see higher incidences of degenerative disease and a greater susceptibility to infection. Aging consumers are adapting to a healthier lifestyle and their desire to improve the quality of life, resulting in a lucrative segment for supplement providers.

“We are very excited about opening this dialogue of communication with X Consul Group. We strongly feel that the market for dietary supplements has yet to achieve a level of saturation, having the opportunity to work with a greatly respected group like X Consul, will offer us a great scope for growth and development,” comments Mr. Harvey Panesar, President of Martin Nutraceuticals Inc. “Having the chance at penetrating a multi-million dollar market of Portugal and Spain and being successful at it will hopefully result in the rest of the EU (European Union) opening its doors to our products.”

For more information, please contact Investor Relations at (973) 351-3868 or http://www.martinnutra.com

To read the complete release, go to http://biz.yahoo.com/bw/070319/20070319005516.html?.v=1

For a Free Newsletter, go to http://www.OTCReporter.com

CybeRelease Gainers are Kronos Incorporated (Nasdaq: KRON), Golden Telecom, Inc. (Nasdaq: GLDN), Sina Corporation (Nasdaq: SINA), Washington Group International, Inc. (Nasdaq: WGII), Shire PLC (Nasdaq: SHPGY), Palomar Medical Technologies, Inc. (Nasdaq: PMTI), i2 Technologies, Inc. (Nasdaq: ITWO) and Ctrip.com International, Ltd. (Nasdaq: CTRP).

CybeRelease Decliners are Trimeris, Inc. (Nasdaq: TRMS), Methanex Corporation (Nasdaq: MEOH), Celebrate Express, Inc. (Nasdaq: BDAY), Progenics Pharmaceuticals Inc. (Nasdaq: PGNX), Equinix, Inc. (Nasdaq: EQIX), Red Robin Gourmet Burgers, Inc. (Nasdaq: RRGB), Tecumseh Products Company (Nasdaq: TECUA) and USA Mobility, Inc. (Nasdaq: USMO).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.

Contact Information

C. P. Barry

Media Contact

CybeRelease.com

Contact via E-mail